SCHEMBL26614149

SCHEMBL26614149

O=C1c2cc([N+](=O)[O-])ccc2-n2c1nc1cc(F)ccc1c2=O

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 15/20 0.73
▸ TDO2 P48775 14/20 0.73
▸ IDO2 Q6ZQW0 10/20 0.73
▸ APAF1 O14727 2/20 0.62
▸ MEN1 O00255 1/20 0.62
▸ NPC1 O15118 1/20 0.62
▸ MITF O75030 1/20 0.62
▸ HSP90AA1 P07900 1/20 0.62
▸ RAB9A P51151 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ CHEK1 O14757 1/20 0.59
▸ PIM1 P11309 1/20 0.59
▸ LIMK1 P53667 1/20 0.59
▸ TYRO3 Q06418 1/20 0.59
▸ MAPK14 Q16539 1/20 0.59
▸ CLK4 Q9HAZ1 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31382878 1.00 IDO1 (0.73) IDO1TDO2IDO2APAF1MEN1
SCHEMBL26614271 0.91 IDO1 (0.76) IDO1TDO2IDO2APAF1MEN1
SCHEMBL31382850 0.91 IDO1 (0.76) IDO1TDO2IDO2APAF1MEN1
SCHEMBL26614196 0.87 IDO1 (0.75) IDO1TDO2IDO2APAF1MEN1
SCHEMBL31382858 0.87 IDO1 (0.75) IDO1TDO2IDO2APAF1MEN1
SCHEMBL4585634 0.87 IDO1 (0.80) IDO1TDO2IDO2APAF1MEN1
SCHEMBL30639093 0.86 IDO1 (0.73) IDO1TDO2IDO2APAF1MEN1
SCHEMBL31382864 0.86 IDO1 (0.73) IDO1TDO2IDO2APAF1MEN1
SCHEMBL31382880 0.86 IDO1 (0.73) IDO1TDO2IDO2APAF1MEN1
SCHEMBL26614143 0.86 IDO1 (0.73) IDO1TDO2IDO2APAF1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 — — US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 — — EP disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 IDO1 2/4885TDO2 8/4885IDO2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback